Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475862 · ClinicalTrials.gov registry record · Phase 1
Nasal Human Abuse Potential of PTI-821
A Phase 1 study, sponsored by Pain Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03475862 is a Phase 1 study that has completed, run by Pain Therapeutics. The registered enrollment target is 38 participants.
The verdict
NCT03475862, a Phase 1 study, has completed, sponsored by Pain Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.
Interventions
- OTHER Placebo
- DRUG Oxycodone
- DRUG OxyContin
- DRUG PTI-821 capsule Manipulated
- DRUG PTI-821 Non-manipulated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03475862
The ClinicalTrials.gov registry entry for NCT03475862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pain Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03475862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03475862 about?
NCT03475862 is a clinical study titled "Nasal Human Abuse Potential of PTI-821". The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.
What is the current status of trial NCT03475862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-05-15. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT03475862?
The interventions under investigation include: Placebo (OTHER), Oxycodone (DRUG), OxyContin (DRUG), PTI-821 capsule Manipulated (DRUG), PTI-821 Non-manipulated (DRUG).
Who is sponsoring clinical trial NCT03475862?
This trial is sponsored by Pain Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.